ArticleFrontiers in cellular and infection microbiology2026
Silver nanoparticles at sub-cytotoxic levels increase enteric pathogen invasion by compromising intestinal epithelial barrier integrity.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Isolation and identification of a chicken-derived Salmonella phage VB-SalS-XND03, Its biological characteristics and application effect against Salmonella infection in chicks.Poultry science · 2026Article
- Gestational and lactational exposure to HIV tri-combination therapy induces sex- and dose-dependent changes in inflammatory cytokine profiles, intestinal permeability, and villi morphology in adult rat offspring.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Silver nanoparticles (AgNPs) are increasingly used due to their antimicrobial properties and incorporated into food packaging and dietary supplements. However, their potential to disrupt intestinal epithelial integrity and enhance susceptibility to bacterial infection remains insufficiently characterized. Building on our previous Methods: This study aimed to examine the effect of 10 nm AgNPs pretreatment to human intestinal epithelial cells (T84 cells) at the sub-cytotoxic concentrations to determine adherence, invasion and intracellular persistence of Results: Pretreatment of intestinal epithelial cells with AgNPs (10 or 20 µg/mL) did not affect bacterial initial adhesion. However, 10 µg/mL AgNPs significantly increased bacterial invasion and intracellular persistence, demonstrating impaired epithelial defenses in a concentration-dependent manner. The preexposure to AgNP upregulated multiple intestinal permeability-associated genes that are involved in tight and gap junctions, focal adhesions, and cytoskeletal remodeling, with the 10 µg/mL concentration and bacterial infection showing the most statistically significant changes. This response suggests a compensatory repair mechanism to maintain barrier integrity, however it was insufficient to prevent pathogen invasion and intracellular survival. Additionally, 10 µg/mL AgNPs pretreatment significantly increased the secretion of proinflammatory cytokines (e.g., IL-18, TNF-α), while decreased the level of important epithelial repair and anti-inflammatory cytokines (e.g., G-CSF, IL-1ra). These results suggest that exposure to AgNPs, even at low concentration, can impair intestinal barrier integrity, hence facilitating pathogen invasion and persistence. Discussion: Given the increasing use of AgNPs into orally ingested consumer products, these results underscore a potential health risk associated with chronic AgNPs ingestion and highlights the need to re-evaluate their safety in the context of gastrointestinal health and host-pathogen interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.